Market Currents

• Monday, November 2, 2009

• 16:20 PM MannKind (MNKD): Q3 EPS of -$0.42 beats by $0.06, on no revenue. "While we continue to be fully engaged in the task of navigating our NDA through the FDA review process, we are continuing to run additional studies of AFRESA." Shares +1.5% AH. (PR) 1 Comment
• 00:10 AM Notable post-market earnings: APC, AXS, CAR, CHK, FST, HL, KGC, MNKD, PFG, RSG, SM, VMC Comment!

• Thursday, December 4, 2008

• 08:57 AM Premarket gainers: MNKD +20%. CS +3%. NOK +3%. WMT +3%. Comment!

• Friday, June 27, 2008

• 13:55 PM With 133M overweight Americans, forward looking predictions for type II diabetes sufferers are downright scary. Three companies that stand to profit. (SNY, NVO, DVA). Three more. (MRK, MNKD, AMLN) Comment!